Oliver Freudenreich

Oliver Freudenreich, M.D., a psychiatrist specializing in clinical psychopharmacology, discusses the groundbreaking potential of GLP-1 agonists in combating weight gain from antipsychotics. He explores the prevalence and associated health risks of this issue, noting the shortcomings of traditional weight management strategies. Delving into mechanisms, he highlights GLP-1's effects on satiety and glucose metabolism. With insights on clinical applications, he emphasizes the urgency of integrating these treatments while continuing essential research.

Oliver Freudenreich, a psychiatrist from Massachusetts General Hospital and Harvard Medical School, delves into groundbreaking Finnish research that tracked 62,000 clozapine patients over 22 years. He discusses the rare side effect agranulocytosis, its long-term risks, and what this means for clozapine prescribing practices. Freudenreich compares clozapine to other antipsychotics, revealing its benefits and mortality rate advantages. The conversation highlights the urgent need for enhanced monitoring and better patient communication in mental health treatment.

Join psychiatrist Oliver Freudenreich, an expert in psychopharmacology from Massachusetts General Hospital, as he sheds light on the complexities of antipsychotic withdrawal. He discusses how psychotic relapse may sometimes be mistaken for withdrawal symptoms. The conversation reveals the common effects of discontinuation, such as insomnia and anxiety, along with risk factors and essential strategies for safe tapering. This insightful dialogue emphasizes the need for careful management and patient communication during this critical transition.

Oliver Freudenreich, a Boston-based psychiatrist and expert at the Psychopharmacology Institute, dives into the intriguing world of high-dose olanzapine as a potential alternative for treatment-resistant schizophrenia. The conversation highlights the challenges and risks associated with doses exceeding FDA limits. Oliver compares high-dose olanzapine to clozapine, discussing its efficacy based on a systematic review of various studies. They stress the necessity for patient-centered care, emphasizing informed discussions about long-term side effects like metabolism and weight gain.

Oliver Freudenreich, a psychiatrist from Boston, dives into the complex relationship between clozapine and obsessive-compulsive symptoms in schizophrenia. He discusses recent research highlighting whether clozapine triggers OCD or if there are deeper psychological mechanisms involved. The conversation covers the prevalence of OCD-like symptoms in clozapine users, the distinction between psychosis and compulsive behaviors, and tailored treatment strategies for improving patient outcomes. With engaging case studies, the episode unpacks the challenges of managing these intertwined symptoms.

Dr. Oliver Freudenreich, a Boston-based psychiatrist, dives into the fascinating world of probiotics and their potential to combat weight gain linked to antipsychotics like olanzapine. He discusses the probiotic Akkermansia muciniphila, suggesting it could be key to maintaining metabolic health. The conversation explores how gut health impacts weight management for patients on antipsychotics. Dr. Freudenreich also highlights the challenges of incorporating probiotics into treatment, paving the way for a holistic approach to psychiatric care.

In this engaging discussion, Oliver Freudenreich, a psychopharmacology expert, explores the revolutionary antipsychotic KarXT, which targets the cholinergic system instead of dopamine pathways. He shares insights from promising Phase 3 trial results, indicating KarXT's potential to treat schizophrenia with fewer motor-related side effects. This innovative approach not only showcases the drug's clinical efficacy but also discusses its potential FDA approval and implications for transforming how schizophrenia is managed.

Oliver Freudenreich, psychiatrist and psychopharmacology expert, breaks down the COaST trial on semaglutide for clozapine-related weight gain. He walks through study design, striking weight-loss results, safety signals and practical barriers to prescribing. Short, clear takes on what the trial shows and what still needs more research.

Join psychiatrist Oliver Freudenreich from Harvard Medical School as he dives into an innovative Mayo Clinic algorithm for selecting antipsychotics for first-episode psychosis. He discusses how the presence of violence influences the choice of medication, recommending options like aripiprazole and olanzapine. He emphasizes the effectiveness and adherence benefits of long-acting injectables and defends olanzapine’s use despite its metabolic risks. The conversation culminates in a practical application of these insights to real cases.

Oliver Freudenreich, a seasoned psychiatrist from Boston specializing in clozapine, shares vital insights on the lesser-known, yet dangerous side effects of this antipsychotic. He highlights the risks of bowel obstruction and pneumonia that often slip under the radar compared to agranulocytosis. Drawing from a landmark Finnish study, Oliver emphasizes the crucial need for vigilant patient monitoring. He also discusses the role of pharmacogenetics in managing these risks, advocating for proactive strategies to enhance patient safety.